Plasma folate, but not homocysteine, is associated with Apolipoprotein A1 levels in a non-fortified population

Lipids in Health and Disease

Johan Hultdin⁴  Jan-Håkan Jansson⁶  Lars Weinehall³  Göran Hallmans²  Owe Johnson¹  Mats Eliasson⁷  Elisabet Söderström⁵ 

[1] Department of Public Health and Clinical Medicine, Medicine, Umeå University, Umeå, Sweden;Department of Public Health and Clinical Medicine, Nutritional Research, Umeå University, Umeå, Sweden;Department of Public Health and Clinical Medicine, Epidemiology and Global Health, Umeå University, Umeå, Sweden;Department of Medical Biosciences, Clinical Chemistry, Umeå University, 901 85, Umeå, Sweden;Department of Clinical Chemistry, Sunderby Hospital, Luleå, Sweden;Department of Medicine-Geriatric, Skellefteå County Hospital, Skellefteå, Sweden;Department of Medicine, Sunderby Hospital, Luleå, Sweden

关键词: Epidemiology;    Folate;    Myocardial infarction;    Homocysteine;    Apolipoprotein;   

Others  :  834638
DOI  :  10.1186/1476-511X-12-74

 received in 2012-12-13, accepted in 2013-05-15,  发布年份 2013

【 摘 要 】

Background

Elevated total plasma homocysteine (tHcy) in humans is associated with cardiovascular disease but prevention trials have failed to confirm causality. Reported reasons for this association have been that homocysteine and its major genetic determinant methylenetetrahydrofolate reductase (MTHFR) may have an effect on HDL and Apolipoprotein (Apo) A1 levels. We wanted to study if tHcy and its major determinants were correlated with Apo A1 levels in a large population without folate fortification.

Methods

This study was a prospective incident nested case-referent study within the Northern Sweden Health and Disease Study Cohort (NSHDSC), including 545 cases with first myocardial infarction and 1054 matched referents, median age at inclusion was 59 years. Univariate and multiple regression analyzes was used to study the associations between apolipoproteins Apo A1 and B, tHcy, folate and vitamin B12 in plasma as well as MTHFR polymorphisms 677C>T and 1298A>C.

Results

Apo A1 and Apo B were strongly associated with the risk of a first myocardial infarction. tHcy was not associated with Apo A1 levels. Instead, folate had an independent positive association with Apo A1 levels in univariate and multiple regression models. The associations were seen in all men and women, among referents but not among cases. MTHFR polymorphisms had no clear effect on Apo A1 levels.

Conclusions

Analyzing over 1500 subjects we found an independent positive association between plasma folate (major dietary determinant of tHcy) and Apo A1 levels among those who later did not develop a first myocardial infarction. No association was seen between tHcy and Apo A1.

【 授权许可】

   
2013 Söderström et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Van Guelpen B, Hultdin J, Johansson I, Witthöft C, Weinehall L, Eliasson M, Hallmans G, Palmqvist R, Jansson JH, Winkvist A: Plasma folate and total homocysteine levels are associated with the risk of myocardial infarction, independently of each other and of renal function. J Intern Med 2009, 266:182-195.
• [2]Wald DS, Law M, Morris JK: Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 2002, 325:1202.
• [3]The Homocysteine Studies Collaboration: Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 2002, 288:2015-2022.
• [4]Ford ES, Smith SJ, Stroup DF, Steinberg KK, Mueller PW, Thacker SB: Homocyst(e)ine and cardiovascular disease: a systematic review of the evidence with special emphasis on case–control studies and nested case–control studies. Int J Epidemiol 2002, 31:59-70.
• [5]Bautista LE, Arenas IA, Penuela A, Martinez LX: Total plasma homocysteine level and risk of cardiovascular disease: a meta-analysis of prospective cohort studies. J Clin Epidemiol 2002, 55:882-887.
• [6]Zylberstein DE, Bengtsson C, Björkelund C, Landaas S, Sundh V, Thelle D, Lissner L: Serum homocysteine in relation to mortality and morbidity from coronary heart disease: a 24-year follow-up of the population study of women in Gothenburg. Circulation 2004, 109:601-606.
• [7]Cui R, Moriyama Y, Koike KA, Date C, Kikuchi S, Tamakoshi A, Iso H: Serum total homocysteine concentrations and risk of mortality from stroke and coronary heart disease in Japanese: The JACC study. Atherosclerosis 2008, 198:412-418.
• [8]Clarke R, Halsey J, Bennett D, Lewington S: Homocysteine and vascular disease: review of published results of the homocysteine-lowering trials. J Inherit Metab Dis 2011, 34:83-91.
• [9]Zhou YH, Tang JY, Wu MJ, Lu J, Wei X, Qin YY, Wang C, Xu JF, He J: Effect of folic acid supplementation on cardiovascular outcomes: a systematic review and meta-analysis. PLoS One 2011, 6:e25142.
• [10]Debreceni B, Debreceni L: Why do homocysteine-lowering B vitamin and antioxidant E vitamin supplementations appear to be ineffective in the prevention of cardiovascular diseases? Cardiovasc Ther 2012, 30:227-233.
• [11]Hofmann MA, Lalla E, Lu Y, Gleason MR, Wolf BM, Tanji N, Ferran LJ Jr, Kohl B, Rao V, Kisiel W: Hyperhomocysteinemia enhances vascular inflammation and accelerates atherosclerosis in a murine model. J Clin Invest 2001, 107:675-683.
• [12]Sharma P, Senthilkumar RD, Brahmachari V, Sundaramoorthy E, Mahajan A, Sharma A, Sengupta S: Mining literature for a comprehensive pathway analysis: a case study for retrieval of homocysteine related genes for genetic and epigenetic studies. Lipids Health Dis 2006, 5:1. BioMed Central Full Text
• [13]Glomset JA: The plasma lecithins:cholesterol acyltransferase reaction. J Lipid Res 1968, 9:155-167.
• [14]Osei-Hwedieh DO, Amar M, Sviridov D, Remaley AT: Apolipoprotein mimetic peptides: Mechanisms of action as anti-atherogenic agents. Pharmacol Ther 2011, 130:83-91.
• [15]Navab M, Reddy ST, Van Lenten BJ, Fogelman AM: HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms. Nat Rev Cardiol 2011, 8:222-232.
• [16]Devlin AM, Lentz SR: ApoA-I: a missing link between homocysteine and lipid metabolism? Circ Res 2006, 98:431-433.
• [17]Stampfer MJ, Malinow MR, Willett WC, Newcomer LM, Upson B, Ullmann D, Tishler PV, Hennekens CH: A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA 1992, 268:877-881.
• [18]Anderson JL, Muhlestein JB, Horne BD, Carlquist JF, Bair TL, Madsen TE, Pearson RR: Plasma homocysteine predicts mortality independently of traditional risk factors and C-reactive protein in patients with angiographically defined coronary artery disease. Circulation 2000, 102:1227-1232.
• [19]Qujeq D, Omran TS, Hosini L: Correlation between total homocysteine, low-density lipoprotein cholesterol and high-density lipoprotein cholesterol in the serum of patients with myocardial infarction. Clin Biochem 2001, 34:97-101.
• [20]Gueant-Rodriguez RM, Spada R, Moreno-Garcia M, Anello G, Bosco P, Lagrost L, Romano A, Elia M, Gueant JL: Homocysteine is a determinant of ApoA-I and both are associated with ankle brachial index, in an ambulatory elderly population. Atherosclerosis 2011, 214:480-485.
• [21]Real JT, Martinez-Hervas S, Garcia-Garcia AB, Chaves FJ, Civera M, Ascaso JF, Carmena R: Association of C677T polymorphism in MTHFR gene, high homocysteine and low HDL cholesterol plasma values in heterozygous familial hypercholesterolemia. J Atheroscler Thromb 2009, 16:815-820.
• [22]Collings A, Raitakari OT, Juonala M, Rontu R, Kahonen M, Hutri-Kahonen N, Ronnemaa T, Marniemi J, Viikari JS, Lehtimaki T: Associations of methylenetetrahydrofolate reductase C677T polymorphism with markers of subclinical atherosclerosis: the Cardiovascular Risk in Young Finns Study. Scand J Clin Lab Invest 2008, 68:22-30.
• [23]Liao D, Tan H, Hui R, Li Z, Jiang X, Gaubatz J, Yang F, Durante W, Chan L, Schafer AI: Hyperhomocysteinemia decreases circulating high-density lipoprotein by inhibiting apolipoprotein A-I Protein synthesis and enhancing HDL cholesterol clearance. Circ Res 2006, 99:598-606.
• [24]Liao D, Yang X, Wang H: Hyperhomocysteinemia and high-density lipoprotein metabolism in cardiovascular disease. Clin Chem Lab Med 2007, 45:1652-1659.
• [25]Xiao Y, Zhang Y, Lv X, Su D, Li D, Xia M, Qiu J, Ling W, Ma J: Relationship between lipid profiles and plasma total homocysteine, cysteine and the risk of coronary artery disease in coronary angiographic subjects. Lipids Health Dis 2011, 10:137. BioMed Central Full Text
• [26]Brattström L, Wilcken DE, Ohrvik J, Brudin L: Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease: the result of a meta-analysis. Circulation 1998, 98:2520-2526.
• [27]Mikael LG, Genest J Jr, Rozen R: Elevated homocysteine reduces apolipoprotein A-I expression in hyperhomocysteinemic mice and in males with coronary artery disease. Circ Res 2006, 98:564-571.
• [28]Schwahn BC, Wang XL, Mikael LG, Wu Q, Cohn J, Jiang H, Maclean KN, Rozen R: Betaine supplementation improves the atherogenic risk factor profile in a transgenic mouse model of hyperhomocysteinemia. Atherosclerosis 2007, 195:e100-107.
• [29]Barter PJ, Rye KA: Homocysteine and cardiovascular disease: is HDL the link? Circ Res 2006, 99:565-566.
• [30]Elshorbagy AK, Valdivia-Garcia M, Graham IM, Palma Reis R, Sales Luis A, Smith AD, Refsum H: The association of fasting plasma sulfur-containing compounds with BMI, serum lipids and apolipoproteins. Nutr Metab Cardiovasc Dis 2012, 22:1031-1038.
• [31]Drenos F, Talmud PJ, Casas JP, Smeeth L, Palmen J, Humphries SE, Hingorani AD: Integrated associations of genotypes with multiple blood biomarkers linked to coronary heart disease risk. Hum Mol Genet 2009, 18:2305-2316.
• [32]Ishimine N, Usami Y, Nogi S, Sumida T, Kurihara Y, Matsuda K, Nakamura K, Yamauchi K, Okumura N, Tozuka M: Identification of N-homocysteinylated apolipoprotein AI in normal human serum. Ann Clin Biochem 2010, 47:453-459.
• [33]Shai I, Stampfer MJ, Ma J, Manson JE, Hankinson SE, Cannuscio C, Selhub J, Curhan G, Rimm EB: Homocysteine as a risk factor for coronary heart diseases and its association with inflammatory biomarkers, lipids and dietary factors. Atherosclerosis 2004, 177:375-381.
• [34]Christensen B, Landaas S, Stensvold I, Djurovic S, Retterstol L, Ringstad J, Berg K, Thelle DS: Whole blood folate, homocysteine in serum, and risk of first acute myocardial infarction. Atherosclerosis 1999, 147:317-326.
• [35]Shidfar F, Froghifar N, Vafa M, Rajab A, Hosseini S, Shidfar S, Gohari M: The effects of tomato consumption on serum glucose, apolipoprotein B, apolipoprotein A-I, homocysteine and blood pressure in type 2 diabetic patients. Int J Food Sci Nutr 2011, 62:289-294.
• [36]Taskinen MR, Sullivan DR, Ehnholm C, Whiting M, Zannino D, Simes RJ, Keech AC, Barter PJ: Relationships of HDL cholesterol, ApoA-I, and ApoA-II with homocysteine and creatinine in patients with type 2 diabetes treated with fenofibrate. Arterioscler Thromb Vasc Biol 2009, 29:950-955.
• [37]Nuno-Ayala M, Guillen N, Navarro MA, Lou-Bonafonte JM, Arnal C, Gascon S, Barranquero C, Godino J, Royo-Canas M, Sarria AJ: Cysteinemia, rather than homocysteinemia, is associated with plasma apolipoprotein A-I levels in hyperhomocysteinemia: lipid metabolism in cystathionine beta-synthase deficiency. Atherosclerosis 2010, 212:268-273.
• [38]Van Guelpen B, Dahlin AM, Hultdin J, Eklof V, Johansson I, Henriksson ML, Cullman I, Hallmans G, Palmqvist R: One-carbon metabolism and CpG island methylator phenotype status in incident colorectal cancer: a nested case-referent study. Cancer Causes Control 2010, 21:557-566.
• [39]Zaina S, Lindholm MW, Lund G: Nutrition and aberrant DNA methylation patterns in atherosclerosis: more than just hyperhomocysteinemia? J Nutr 2005, 135:5-8.
• [40]Lillycrop KA, Phillips ES, Jackson AA, Hanson MA, Burdge GC: Dietary protein restriction of pregnant rats induces and folic acid supplementation prevents epigenetic modification of hepatic gene expression in the offspring. J Nutr 2005, 135:1382-1386.
• [41]Gueant JL, Namour F, Gueant-Rodriguez RM, Daval JL: Folate and fetal programming: a play in epigenomics. Trends Endocrinol Metabin press
• [42]Rader DJ: Molecular regulation of HDL metabolism and function: implications for novel therapies. J Clin Invest 2006, 116:3090-3100.
• [43]Luc G, Jacob N, Bouly M, Fruchart JC, Staels B, Giral P: Fenofibrate increases homocystinemia through a PPARalpha-mediated mechanism. J Cardiovasc Pharmacol 2004, 43:452-453.
• [44]Mikael LG, Rozen R: Homocysteine modulates the effect of simvastatin on expression of ApoA-I and NF-kappaB/iNOS. Cardiovasc Res 2008, 80:151-158.
• [45]Brinton EA: Effects of ethanol intake on lipoproteins. Curr Atheroscler Rep 2012, 14:108-114.
• [46]Hallmans G, Ågren Å, Johansson G, Johansson A, Stegmayr B, Jansson JH, Lindahl B, Rolandsson O, Söderberg S, Nilsson M: Cardiovascular disease and diabetes in the Northern Sweden Health and Disease Study Cohort - evaluation of risk factors and their interactions. Scand J Public Health Suppl 2003, 61:18-24.
• [47]Stegmayr B, Lundberg V, Asplund K: The events registration and survey procedures in the Northern Sweden MONICA Project. Scand J Public Health Suppl 2003, 61:9-17.
• [48]Weinehall L, Hallgren CG, Westman G, Janlert U, Wall S: Reduction of selection bias in primary prevention of cardiovascular disease through involvement of primary health care. Scand J Prim Health Care 1998, 16:171-176.
• [49]Hagstad A, Johansson S, Wilhelmsson C, Janson PO: Gynaecology of middle-aged women–menstrual and reproductive histories. Maturitas 1985, 7:99-113.